GlobeNewswire·Jul 28, 2026, 8:00 AM ET

YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada

YD Bio Limited announced a six-month pilot collaboration to evaluate the scalability of cross-border, physician-ordered blood-based OkaiDx laboratory-developed tests in Canada.
The pilot involves YD Bio, YD Bio US, EG BioMed US, and Numia Health under an agreement dated July 23, 2026.
The initiative targets up to 50 patient episodes in the Lower Mainland region of British Columbia for breast, colorectal, pancreatic, liver, & gastrointestinal cancers.
Numia Health will manage physician requisitions, mobile blood collection, specimen preparation, & logistics, while EG BioMed US will perform laboratory analysis at its CLIA-certified, CAP-accredited facility in Bothell, Washington.
This pilot represents YD Bio's first structured clinical-access initiative in Canada & supports the company's strategy of building a cross-border molecular diagnostics platform through an asset-light, partnership-driven model.
OkaiDx tests are laboratory-developed tests performed exclusively at EG BioMed US's laboratory at the request of a prescribing healthcare provider & have not been approved by the U.S. FDA or Health Canada.
The pilot aims to assess operational workflows, specimen logistics, & patient experience before parties consider any broader non-exclusive commercial collaboration.
Dr. Ethan Shen, CEO of YD Bio, stated the collaboration reflects a strategy to expand patient access to advanced molecular diagnostics while maintaining laboratory quality & regulatory standards.